In the orthotopic model, CXCR4 antagonism by POL5551 combined with the anti-VEGF antibody B20-4.1.1 decreased glioma invasiveness and vascular density, resulting in a valuable strategy to overcome antiangiogenic therapy resistance, as revealed by both in vitro and in vivo experiments [143]. Here, CXCR4 is linked to glioma.